Management of indolent lymphoma: Where are we now and where are we going

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Indolent lymphoma comprises a unique and challenging subset of non-Hodgkin lymphoma (NHL). While definitions of indolence will vary, the most common indolent NHL subtypes include follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma. Patients with indolent NHL (iNHL) excluding those with rare localized presentations are often met with an incurable but highly treatable NHL. In the rituximab era, response rates are approaching 90% with rituximab plus chemotherapy and time to next treatment are beginning to be measured in years. As a result of a prolonged natural history, we are encountering a gridlock of novel regimens and agents that appropriately fill peer-reviewed journals. In this review, we tackle a spectrum of topics in the management of indolent lymphoma including the initial approach to the newly diagnosed patient, approaches to first cytotoxic chemotherapy, maintenance and consolidation techniques, as well as highlight promising treatments on the horizon in iNHL. Clinicians continue to face tough choices in the management of iNHL. Through well-thought out clinical trials and peer-reviewed vetting of data we will continue to determine how to best manage the clinical continuum that is iNHL.

Original languageEnglish (US)
Pages (from-to)279-288
Number of pages10
JournalBlood Reviews
Volume26
Issue number6
DOIs
StatePublished - Nov 1 2012

Fingerprint

Non-Hodgkin's Lymphoma
Lymphoma
Consolidation Chemotherapy
Follicular Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Natural History
Maintenance
Clinical Trials
Drug Therapy
Therapeutics
Rituximab

Keywords

  • Bendamustine
  • Bortezomib
  • Bruton's tyrosine kinase
  • CD20
  • Cyclophosphamide
  • Doxorubicin
  • Fludarabine
  • Follicular
  • Histone deacetylase inhibitors
  • Indolent lymphoma
  • Lenalidomide
  • MTOR
  • Marginal zone
  • Non-Hodgkin
  • PI3K
  • Rituximab
  • Small lymphocytic

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Management of indolent lymphoma : Where are we now and where are we going. / Lunning, Matthew A; Vose, Julie Marie.

In: Blood Reviews, Vol. 26, No. 6, 01.11.2012, p. 279-288.

Research output: Contribution to journalArticle

@article{f7c467a581364d1d92eddd4f5cc69edf,
title = "Management of indolent lymphoma: Where are we now and where are we going",
abstract = "Indolent lymphoma comprises a unique and challenging subset of non-Hodgkin lymphoma (NHL). While definitions of indolence will vary, the most common indolent NHL subtypes include follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma. Patients with indolent NHL (iNHL) excluding those with rare localized presentations are often met with an incurable but highly treatable NHL. In the rituximab era, response rates are approaching 90{\%} with rituximab plus chemotherapy and time to next treatment are beginning to be measured in years. As a result of a prolonged natural history, we are encountering a gridlock of novel regimens and agents that appropriately fill peer-reviewed journals. In this review, we tackle a spectrum of topics in the management of indolent lymphoma including the initial approach to the newly diagnosed patient, approaches to first cytotoxic chemotherapy, maintenance and consolidation techniques, as well as highlight promising treatments on the horizon in iNHL. Clinicians continue to face tough choices in the management of iNHL. Through well-thought out clinical trials and peer-reviewed vetting of data we will continue to determine how to best manage the clinical continuum that is iNHL.",
keywords = "Bendamustine, Bortezomib, Bruton's tyrosine kinase, CD20, Cyclophosphamide, Doxorubicin, Fludarabine, Follicular, Histone deacetylase inhibitors, Indolent lymphoma, Lenalidomide, MTOR, Marginal zone, Non-Hodgkin, PI3K, Rituximab, Small lymphocytic",
author = "Lunning, {Matthew A} and Vose, {Julie Marie}",
year = "2012",
month = "11",
day = "1",
doi = "10.1016/j.blre.2012.09.004",
language = "English (US)",
volume = "26",
pages = "279--288",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - Management of indolent lymphoma

T2 - Where are we now and where are we going

AU - Lunning, Matthew A

AU - Vose, Julie Marie

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Indolent lymphoma comprises a unique and challenging subset of non-Hodgkin lymphoma (NHL). While definitions of indolence will vary, the most common indolent NHL subtypes include follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma. Patients with indolent NHL (iNHL) excluding those with rare localized presentations are often met with an incurable but highly treatable NHL. In the rituximab era, response rates are approaching 90% with rituximab plus chemotherapy and time to next treatment are beginning to be measured in years. As a result of a prolonged natural history, we are encountering a gridlock of novel regimens and agents that appropriately fill peer-reviewed journals. In this review, we tackle a spectrum of topics in the management of indolent lymphoma including the initial approach to the newly diagnosed patient, approaches to first cytotoxic chemotherapy, maintenance and consolidation techniques, as well as highlight promising treatments on the horizon in iNHL. Clinicians continue to face tough choices in the management of iNHL. Through well-thought out clinical trials and peer-reviewed vetting of data we will continue to determine how to best manage the clinical continuum that is iNHL.

AB - Indolent lymphoma comprises a unique and challenging subset of non-Hodgkin lymphoma (NHL). While definitions of indolence will vary, the most common indolent NHL subtypes include follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma. Patients with indolent NHL (iNHL) excluding those with rare localized presentations are often met with an incurable but highly treatable NHL. In the rituximab era, response rates are approaching 90% with rituximab plus chemotherapy and time to next treatment are beginning to be measured in years. As a result of a prolonged natural history, we are encountering a gridlock of novel regimens and agents that appropriately fill peer-reviewed journals. In this review, we tackle a spectrum of topics in the management of indolent lymphoma including the initial approach to the newly diagnosed patient, approaches to first cytotoxic chemotherapy, maintenance and consolidation techniques, as well as highlight promising treatments on the horizon in iNHL. Clinicians continue to face tough choices in the management of iNHL. Through well-thought out clinical trials and peer-reviewed vetting of data we will continue to determine how to best manage the clinical continuum that is iNHL.

KW - Bendamustine

KW - Bortezomib

KW - Bruton's tyrosine kinase

KW - CD20

KW - Cyclophosphamide

KW - Doxorubicin

KW - Fludarabine

KW - Follicular

KW - Histone deacetylase inhibitors

KW - Indolent lymphoma

KW - Lenalidomide

KW - MTOR

KW - Marginal zone

KW - Non-Hodgkin

KW - PI3K

KW - Rituximab

KW - Small lymphocytic

UR - http://www.scopus.com/inward/record.url?scp=84868201843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868201843&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2012.09.004

DO - 10.1016/j.blre.2012.09.004

M3 - Article

C2 - 23063143

AN - SCOPUS:84868201843

VL - 26

SP - 279

EP - 288

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

IS - 6

ER -